Nové možnosti antikoagulačnej liečby u onkologických pacientov // SOLEN

Onkológia 5/2018

New options of anticoagulant therapy in oncologic patients

Patients with active oncological disease are at high risk of thromboembolic complications. However they are also at high risk of bleeding complications. Long term standard anticoagulation therapy has been low molecular weight heparin. Comparing to warfarine it showed greater efficacy. Its main disadvantage in the need of long term therapy is parenteral route of application that is associated with the risk of non-compliance. The perspective alternative for the future could be the group of new oral anticoagulants. They demonstrated higher efficacy without the need of routine laboratory monitoring in comparison to warfarin. However, their level of Evidence Based Medicine has been limited so far.

Keywords: thromboembolic disease, new oral anticoagulants, oncologic patient